株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

好酸球性食道炎:パイプライン分析

Eosinophilic Esophagitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 246006
出版日 ページ情報 英文 68 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
好酸球性食道炎:パイプライン分析 Eosinophilic Esophagitis - Pipeline Review, H2 2016
出版日: 2016年10月19日 ページ情報: 英文 68 Pages
概要

好酸球性食道炎とは、食物・アレルゲン・呑酸などに反応して、好酸球(白血球の一種)が食道組織内部に蓄積されるという症状です。主な症状として、体重減少や腹痛、吐き気・嘔吐、咳、胸焼け、胸痛などが挙げられます。疾病素質には、HIV/AIDS感染に伴う免疫系の弱体化や、糖尿病、白血病、リンパ腫、他の自己免疫疾患、化学療法、アスピリン剤・抗炎症剤、慢性嘔吐、肥満、飲酒、喫煙などがあります。主な治療法には、抗ウイルス剤、抗真菌薬、鎮痛剤などが含まれています。

当レポートでは、世界各国での好酸球性食道炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

好酸球性食道炎の概要

治療薬の開発

  • 好酸球性食道炎向けパイプライン製品:概要
  • 好酸球性食道炎向けパイプライン製品:比較分析

各企業で開発中の好酸球性食道炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

好酸球性食道炎治療薬:開発中の製品の一覧(企業別)

好酸球性食道炎治療薬の開発に従事している企業

  • Allergan Plc
  • DBV Technologies S.A.
  • Dr. Falk Pharma GmbH
  • Novartis AG
  • Receptos, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Shire Plc

好酸球性食道炎:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • Allergen for Milk Allergy
  • budesonide
  • budesonide
  • dectrekumab
  • dupilumab
  • EUR-1100
  • Qi-406
  • RPC-4046

好酸球性食道炎治療薬:パイプライン製品の最新動向

好酸球性食道炎治療薬:開発が休止状態の製品

好酸球性食道炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8557IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2016, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 2 and 3 respectively for Eosinophilic Esophagitis.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Eosinophilic Esophagitis Overview
  • Therapeutics Development
    • Pipeline Products for Eosinophilic Esophagitis - Overview
  • Eosinophilic Esophagitis - Therapeutics under Development by Companies
  • Eosinophilic Esophagitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Eosinophilic Esophagitis - Products under Development by Companies
  • Eosinophilic Esophagitis - Companies Involved in Therapeutics Development
    • Adare Pharmaceuticals, Inc.
    • Calypso Biotech SA
    • Celgene Corporation
    • DBV Technologies S.A.
    • Dr. Falk Pharma GmbH
    • Novartis AG
    • Panmira Pharmaceuticals, LLC.
    • Quorum Innovations LLC
    • Regeneron Pharmaceuticals Inc
    • Shire Plc
  • Eosinophilic Esophagitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Allergen for Milk Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-461 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CALY-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dectrekumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dupilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluticasone propionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluticasone propionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Qi-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPC-4046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Eosinophilic Esophagitis - Dormant Projects
  • Eosinophilic Esophagitis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy
      • Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions
      • Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis
      • Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin Milk in Milk-Induced Eosinophilic Esophagitis in Children
      • Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
      • Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients
      • Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis
      • May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children
      • Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis
      • May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis
      • May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Eosinophilic Esophagitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals, Inc., H2 2016
  • Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Celgene Corporation, H2 2016
  • Eosinophilic Esophagitis - Pipeline by DBV Technologies S.A., H2 2016
  • Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Novartis AG, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Panmira Pharmaceuticals, LLC., H2 2016
  • Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Shire Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Eosinophilic Esophagitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Eosinophilic Esophagitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top